Biogen Inc. Revenue 2007–2025
Biogen Inc. annual/quarterly revenue history and growth rate from 2007 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Biogen Inc. revenue for the quarter ending March 31, 2026 was 2.5 B, a 1.93% increase year-over-year.
- Biogen Inc. revenue for the twelve months ending March 31, 2026 was 10.1 B, a 3.46% increase year-over-year.
- Biogen Inc. annual revenue for 2025 was 9.9 B, a 2.22% increase from 2024.
- Biogen Inc. annual revenue for 2024 was 9.7 B, a 1.62% decrease from 2023.
- Biogen Inc. annual revenue for 2023 was 9.8 B, a 3.32% decrease from 2022.
- Biogen Inc. annual revenue for 2022 was 10.2 B.
Biogen Inc. (BIIB) — Frequently Asked Questions
Biogen Inc. (BIIB) is a publicly traded US company in the Healthcare sector. It has a market capitalization of $28.57B. In fiscal 2025 it reported revenue of $9.89B and net income of $1.29B. Explore BIIB's stock price, financial statements, earnings history, margins and key ratios below.
What is Biogen Inc.'s market cap?
Biogen Inc. (BIIB) has a market capitalization of $28.57B.
What is the BIIB stock price?
BIIB trades at $194.24 (-2.44% on the day).
How much revenue does Biogen Inc. make?
Biogen Inc. reported revenue of $9.89B in fiscal 2025.
Is BIIB profitable?
In fiscal 2025, Biogen Inc. reported net income of $1.29B.